3/4
07:43 am
xers
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio [Seeking Alpha]
Low
Report
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio [Seeking Alpha]
3/2
04:43 pm
xers
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
3/2
12:53 pm
xers
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/2
12:36 pm
xers
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
3/2
11:05 am
xers
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/2
07:19 am
xers
Xeris Biopharma: Q4 Earnings Snapshot [Yahoo! Finance]
High
Report
Xeris Biopharma: Q4 Earnings Snapshot [Yahoo! Finance]
3/2
07:13 am
xers
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance [Yahoo! Finance]
Medium
Report
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance [Yahoo! Finance]
3/2
07:02 am
xers
Xeris Pharmaceuticals GAAP EPS of $0.06 beats by $0.03, revenue of $85.81M misses by $0.19M [Seeking Alpha]
High
Report
Xeris Pharmaceuticals GAAP EPS of $0.06 beats by $0.03, revenue of $85.81M misses by $0.19M [Seeking Alpha]
3/2
07:00 am
xers
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
High
Report
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
3/1
07:02 pm
xers
A Look At Xeris Biopharma Holdings (XERS) Valuation As It Fights To Protect Recorlev Exclusivity [Yahoo! Finance]
Low
Report
A Look At Xeris Biopharma Holdings (XERS) Valuation As It Fights To Protect Recorlev Exclusivity [Yahoo! Finance]
2/26
06:14 pm
xers
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit [Yahoo! Finance]
Medium
Report
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit [Yahoo! Finance]
2/26
05:55 pm
xers
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
Medium
Report
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
2/17
07:52 am
xers
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 [Yahoo! Finance]
Low
Report
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 [Yahoo! Finance]
2/17
07:30 am
xers
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Low
Report
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
1/23
05:09 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Xeris Biopharma (NASDAQ:XERS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/10
09:26 pm
xers
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? [Yahoo! Finance]
1/10
02:58 pm
xers
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns [Yahoo! Finance]
Low
Report
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns [Yahoo! Finance]
1/10
04:43 am
xers
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents [Yahoo! Finance]
Low
Report
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents [Yahoo! Finance]
1/9
08:38 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
1/8
07:27 am
xers
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue [Yahoo! Finance]
Medium
Report
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue [Yahoo! Finance]
1/8
07:00 am
xers
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
High
Report
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
1/2
04:15 pm
xers
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/2
12:50 am
xers
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday [Yahoo! Finance]
Medium
Report
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday [Yahoo! Finance]
1/1
10:55 pm
xers
US FDA declines to approve Corcept's drug for rare hormonal disorder [Yahoo! Finance]
Medium
Report
US FDA declines to approve Corcept's drug for rare hormonal disorder [Yahoo! Finance]
12/18
01:07 am
xers
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) [Seeking Alpha]
Low
Report
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) [Seeking Alpha]